公开(公告)号：US07572778B2

公开(公告)日：2009-08-11

申请号：US10563480

申请日：2004-07-06

申请人： Giuseppe Giannini ,  Domenico Alloatti ,  Marcella Marcellini ,  Mauro Marzi ,  Teresa Riccioni ,  Maria Ornella Tinti

发明人： Giuseppe Giannini ,  Domenico Alloatti ,  Marcella Marcellini ,  Mauro Marzi ,  Teresa Riccioni ,  Maria Ornella Tinti

IPC分类号： A61K31/66 ,  C07F9/02

CPC分类号： C07C217/84 ,  C07C43/23 ,  C07F9/12

摘要： The present invention is related to new derivatives of Combretastatin, of Formula obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation—as anticancer and/or antiangiogenic activity, in a mammal—to pharmaceutical compositions comprising these compounds.

摘要翻译： 本发明涉及通过全合成获得的配方的Combretastatin的新衍生物。 为每种化合物开发的策略是i）在烯属结合物上取代卤素（即氟原子）至氢; ii）用天然产物中的芳族环与氨基 - 芳香环取代。 所述化合物识别并结合微管蛋白部位：可用于治疗在哺乳动物中由包含这些化合物的药物组合物中由细胞增殖引起或加剧的病理状态 - 作为抗癌和/或抗血管生成活性。

公开(公告)号：US20060160778A1

公开(公告)日：2006-07-20

申请号：US10563480

申请日：2004-07-06

申请人： Giuseppe Giannini ,  Domenico Alloatti ,  Marcella Marcellini ,  Mauro Marzi ,  Teresa Riccioni ,  Maria Tinti

发明人： Giuseppe Giannini ,  Domenico Alloatti ,  Marcella Marcellini ,  Mauro Marzi ,  Teresa Riccioni ,  Maria Tinti

IPC分类号： A61K31/66 ,  C07F9/02 ,  A61K31/135

CPC分类号： C07C217/84 ,  C07C43/23 ,  C07F9/12

摘要： The present invention is related to new derivatives of Combretastatin, of Formula obtained by total synthesis. The strategy developed for each of the compounds is to i) replace a halogen (i.e. fluorine atom) to hydrogen on olefinic bound; ii) replace an aromatic ring in a natural product with an amino-aromatic ring. Said compounds recognize and bind the tubulin site: are useful for treating pathological states which arise from or are exacerbated by cell proliferation—as anticancer and/or antiangiogenic activity, in a mammal—to pharmaceutical compositions comprising these compounds.